Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited Fundamental Analysis
Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO) shows moderate financial fundamentals with a PE ratio of 58.06, profit margin of 45.79%, and ROE of 47.46%. The company generates $0.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 80.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze SHUKRAPHAR.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSHUKRAPHAR.BO demonstrates superior asset utilization.
Valuation Score
ModerateSHUKRAPHAR.BO shows balanced valuation metrics.
Growth Score
WeakSHUKRAPHAR.BO faces weak or negative growth trends.
Financial Health Score
ExcellentSHUKRAPHAR.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateSHUKRAPHAR.BO maintains healthy but balanced margins.
Key Financial Metrics
Is SHUKRAPHAR.BO Expensive or Cheap?
P/E Ratio
SHUKRAPHAR.BO trades at 58.06 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SHUKRAPHAR.BO's PEG of -2.11 indicates potential undervaluation.
Price to Book
The market values Shukra Pharmaceuticals Limited at 25.73 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 42.19 times EBITDA. This signals the market has high growth expectations.
How Well Does SHUKRAPHAR.BO Make Money?
Net Profit Margin
For every $100 in sales, Shukra Pharmaceuticals Limited keeps $45.79 as profit after all expenses.
Operating Margin
Core operations generate 50.22 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $47.46 in profit for every $100 of shareholder equity.
ROA
Shukra Pharmaceuticals Limited generates $33.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shukra Pharmaceuticals Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Shukra Pharmaceuticals Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
SHUKRAPHAR.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
58.06
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
25.73
vs 25 benchmark
P/S Ratio
Price to sales ratio
26.87
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.06
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.80
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.47
vs 25 benchmark
ROA
Return on assets percentage
0.33
vs 25 benchmark
ROCE
Return on capital employed
0.46
vs 25 benchmark
How SHUKRAPHAR.BO Stacks Against Its Sector Peers
| Metric | SHUKRAPHAR.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 58.06 | 29.45 | Worse (Expensive) |
| ROE | 47.46% | 779.00% | Weak |
| Net Margin | 45.79% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.06 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 3.80 | 4.65 | Strong Liquidity |
| ROA | 33.43% | -19344.00% (disorted) | Strong |
SHUKRAPHAR.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shukra Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation